Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

firstwordpharma.com
firstwordpharma.com > story > 7983565

AstraZeneca's oral SERD stumbles in Phase III first-line breast cancer trial

2+ hour, 55+ min ago   (12+ words) firstwordpharma.com...

firstwordpharma.com
firstwordpharma.com > story > 7973027

Friday Five??? Novartis' stumbles spark boardroom backlash, Nodthera name drops, FDA throws wrench into Biohaven deal???and more

2+ day, 8+ hour ago   (19+ words) Friday Five – Novartis' stumbles spark boardroom backlash, Nodthera name drops, FDA throws wrench into Biohaven deal…and more firstwordpharma.com...

FirstWord PHARMA
firstwordpharma.com > story > 7972962

AbbVie aims to expand Qulipta's label into new migraine market

2+ day, 9+ hour ago   (12+ words) FirstWord PHARMA...

FirstWord Pharma
firstwordpharma.com > story > 7969518

NodThera rebrands as Rezera, charts registrational path for PAD drug

3+ day, 2+ hour ago   (12+ words) FirstWord Pharma...

FirstWord Pharma
firstwordpharma.com > story > 7966708

Physician Views Results: Neurologists express cautious optimism for BTK inhibitors in MS

3+ day, 20+ hour ago   (14+ words) FirstWord Pharma...

FirstWord Pharma
firstwordpharma.com > story > 7967524

TwoStep's take on targeting solid tumours gains backing from Merck KGaA, Pfizer venture arms

3+ day, 16+ hour ago   (16+ words) FirstWord Pharma...

FirstWord Pharma
firstwordpharma.com > story > 7967798

Beeline buzzes ahead to pivotal lupus trials after mid-stage success

3+ day, 15+ hour ago   (12+ words) FirstWord Pharma...

FirstWord Pharma
firstwordpharma.com > story > 7963969

Inhibrx touts HNSCC subgroup data, eyes accelerated pathway for OX40 agonist

4+ day, 9+ hour ago   (13+ words) FirstWord Pharma...

FirstWord PHARMA
firstwordpharma.com > story > 7963831

AI analysis from Brainomix adds to evidence backing Endeavor's IPF therapy

4+ day, 12+ hour ago   (13+ words) FirstWord PHARMA...

FirstWord PHARMA
firstwordpharma.com > story > 7961829

Pharvaris' oral HAE hopeful significantly cuts attacks in pivotal study

4+ day, 14+ hour ago   (12+ words) FirstWord PHARMA...